1
|
Kiryanov A, Natala S, Jones B, McBride C, Feher V, Lam B, Liu Y, Honda K, Uchiyama N, Kawamoto T, Hikichi Y, Zhang L, Hosfield D, Skene R, Zou H, Stafford J, Cao X, Ichikawa T. Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors. Bioorg Med Chem Lett 2017; 27:1311-1315. [PMID: 28169164 DOI: 10.1016/j.bmcl.2016.10.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 10/04/2016] [Accepted: 10/05/2016] [Indexed: 11/23/2022]
Abstract
Using structure-based drug design, we identified a novel series of 5,6-dihydroimidazolo[1,5-f]pteridine PLK1 inhibitors. Rational improvements to compounds of this class resulted in single-digit nanomolar enzyme and cellular activity against PLK1, and oral bioavailability. Compound 1 exhibits >7 fold induction of phosphorylated Histone H3 and is efficacious in an in vivo HT-29 tumor xenograft model.
Collapse
Affiliation(s)
- Andre Kiryanov
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA.
| | - Srinivasa Natala
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Benjamin Jones
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | | | - Victoria Feher
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Betty Lam
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Yan Liu
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Kouhei Honda
- Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraokahigashi, Fujisawa, Kanagawa 251-855, Japan
| | - Noriko Uchiyama
- Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraokahigashi, Fujisawa, Kanagawa 251-855, Japan
| | - Tomohiro Kawamoto
- Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraokahigashi, Fujisawa, Kanagawa 251-855, Japan
| | - Yuichi Hikichi
- Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraokahigashi, Fujisawa, Kanagawa 251-855, Japan
| | - Lilly Zhang
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - David Hosfield
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Robert Skene
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Hua Zou
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Jeffrey Stafford
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Xiaodong Cao
- Takeda California, 10410 Science Center Drive, San Diego 92121, USA
| | - Takashi Ichikawa
- Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraokahigashi, Fujisawa, Kanagawa 251-855, Japan
| |
Collapse
|
2
|
Nie Z, Feher V, Natala S, McBride C, Kiryanov A, Jones B, Lam B, Liu Y, Kaldor S, Stafford J, Hikami K, Uchiyama N, Kawamoto T, Hikichi Y, Matsumoto SI, Amano N, Zhang L, Hosfield D, Skene R, Zou H, Cao X, Ichikawa T. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorg Med Chem Lett 2013; 23:3662-6. [PMID: 23664874 DOI: 10.1016/j.bmcl.2013.02.083] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2012] [Revised: 02/14/2013] [Accepted: 02/19/2013] [Indexed: 11/28/2022]
Abstract
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.
Collapse
Affiliation(s)
- Zhe Nie
- Takeda California, 10410 Science Center Drive, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|